Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy

Pediatrics

Volumn 117, Issue 4, 2006, Pages 1440-1443

  Krishnan, Sankaran ^a   Banquet, Agnes ^a   Newman, Leonard ^a   Katta, Umadevi ^b   Patil, Asawari ^b   Dozor, Allen J ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANAMNESIS; ARTICLE; BRONCHIOLITIS OBLITERANS; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG GRANULOMA; MALE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT RESPONSE; DISEASE COURSE; GRANULOMA; LUNG; LUNG DISEASE; PATHOLOGY; PNEUMONIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; GRANULOMA; HUMANS; LUNG; LUNG DISEASES; MALE; PNEUMONIA;

EID: 33646356475     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1559     Document Type: Article

References (20)

1. Feldman M, Scharschmidt BF, Sleisenger MH, Fordtran JS, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 7th ed, 2002:2005-2038
2. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am. 1995;24:633-646
3. Lucero PF, Frey WC, Shaffer RT, Morris MJ. Granulomatous lung masses in an elderly patient with inactive Crohn's disease. Inflamm Bowel Dis. 2001;7:256-259
4. Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med. 1976;136:454-459
5. Omori H, Asahi H, Inoue Y, Irinoda T, Saito K. Pulmonary involvement in Crohn's disease report of a case and review of the literature. Inflamm Bowel Dis. 2004;10:129-134
6. Faller M, Gasser B, Massard G, Pauli G, Quoix E. Pulmonary migratory infiltrates and pachypleuritis in a patient with Crohn's disease. Respiration. 2000;67:459-463
7. Golpe R, Mateos A, Perez-Valcarcel J, Lapena JA, Garcia-Figueiras R, Blanco J. Multiple pulmonary nodules in a patient with Crohn's disease. Respiration. 2003;70:306-309
8. Al-Binali AM, Scott B, Al-Garni A, Montgomery M, Robertson M. Granulomatous pulmonary disease in a child: an unusual presentation of Crohn's disease. Pediatr Pulmonol. 2003;36:76-80
9. Bentur L, Lachter J, Koren I, et al. Severe pulmonary disease in association with Crohn's disease in a 13-year-old girl. Pediatr Pulmonol. 2000;29:151-154
10. Calder CJ, Lacy D, Raafat F, Weller PH, Booth IW. Crohn's disease with pulmonary involvement in a 3 year old boy. Gut. 1993;34:1636-1638
11. Puntis JW, Tarlow MJ, Raafat F, Booth IW. Crohn's disease of the lung. Arch Dis Child. 1990;65:1270-1271
12. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497
13. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769
14. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196
15. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194
16. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111
17. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2003;36:632-636
18. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838
19. Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Clinical outcome and safety of periodic infliximab therapy in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr. 2004;39:302-303
20. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750